The PGE2, PGI2, and LTB4 pathways have been linked with clinical progression through the PGE2 receptor PTGER3 on tumor cells, expression of the PGI2-synthesizing enzyme PTGIS by tumor cells and TAMs, as well as release of LTB4 into the TME by both cell types (52). The gene discussed is PTGER3; the disease is neoplasm.